Patents by Inventor Eri Inoue

Eri Inoue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agent for therapeutic treatment of optic nerve diseases and the like
    Patent number: 7638516
    Abstract: The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: December 29, 2009
    Assignee: Mei Co., Ltd.
    Inventors: Tomiya Mano, Shunji Sogou, Eri Inoue
  • Agent for therapeutic treatment of optic nerve diseases and the like
    Publication number: 20060247293
    Abstract: The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.
    Type: Application
    Filed: June 30, 2006
    Publication date: November 2, 2006
    Inventors: Tomiya Mano, Shunji Sogou, Eri Inoue
  • Peptide having angiotensin converting enzyme inhibitory effect
    Patent number: 7022676
    Abstract: A peptide Met-Lys-Pro, which is obtained by chemical synthesis ot hydrolysis of casein, is used as the active ingredient of angiotensin converting enzyme inhibitors or hypotensive drugs.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: April 4, 2006
    Assignee: Morinaga Milk Industry Co., Ltd.
    Inventors: Yoshitaka Tamura, Hiroshi Miyakawa, Akio Yamada, Hitoshi Saito, Yasushi Kawaguchi, Hiroshi Ochi, Tomoko Ide, Eri Inoue
  • Novel peptide having angiotensin convertase inibitory effect
    Publication number: 20050004041
    Abstract: A peptide Met-Lys-Pro, which is obtained by chemical synthesis ot hydrolysis of casein, is used as the active ingredient of angiotensin converting enzyme inhibitors or hypotensive drugs.
    Type: Application
    Filed: November 21, 2002
    Publication date: January 6, 2005
    Inventors: Yoshitaka Tamura, Hiroshi Miyakawa, Akio Yamada, Hitoshi Saito, Yasushi Kawaguchi, Hiroshi Ochi, Tomoko Ide, Eri Inoue
  • Remedial agent for optic nerve disease and the like
    Publication number: 20030109566
    Abstract: The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.
    Type: Application
    Filed: December 27, 2002
    Publication date: June 12, 2003
    Inventors: Tomiya Mano, Shunji Sogou, Eri Inoue
  • Pharmaceutical composition
    Patent number: 5871739
    Abstract: A pharmaceutical composition comprising, as an active ingredient, a lens antigen which induces a lens cell damaging immune response or a microorganism capable of expressing a lens antigen which induces a lens cell damaging immune response. The pharmaceutical composition of the present invention containing, as an active ingredient, a lens antigen or a microorganism capable of expressing said antigen shows markedly superior inhibitory effects on the increase of an anti-lens protein antibody titer. Therefore, it most probably treats or prevents cataract effectively, and delays onset of cataract. Thus, the composition is extremely useful for cataract patients and reserve patients of cataract.
    Type: Grant
    Filed: October 11, 1996
    Date of Patent: February 16, 1999
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventor: Eri Inoue
  • Pharmaceutical use of pyridoxal derivative
    Patent number: 5441972
    Abstract: A novel use of the compound of the formula ##STR1## wherein R.sub.1 is hydrogen atom or lower alkyl and R.sub.2 is hydrogen atom or phosphoric acid group, or a pharmacologically acceptable salt thereof for preventing and treating cataract. The compounds of the formula (I) and pharmacologically acceptable salts thereof of the present invention inhibit initial changes in the lens, such as vacuolation and trochoidal change, and almost completely inhibit a decrease in the amounts of reduced glutathione and cysteine in the lens, so that they are advantageously used for the prevention of the onset and progress of cataract.
    Type: Grant
    Filed: April 4, 1994
    Date of Patent: August 15, 1995
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Kazumi Ogata, Shunji Sogo, Eri Inoue